Bristol-Myers Squibb Co. (BMY)

51.66
0.83 1.60
NYSE : Health Technology
Prev Close 50.83
Open 51.33
Day Low/High 50.92 / 51.87
52 Wk Low/High 44.30 / 70.05
Volume 15.45M
Avg Volume 13.38M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 82.98B
EPS 3.00
P/E Ratio 16.78
Div & Yield 1.64 (3.16%)

Latest News

European Commission Approves Bristol-Myers Squibb's Sprycel (dasatinib) In Combination With Chemotherapy For Treatment Of Pediatric Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

European Commission Approves Bristol-Myers Squibb's Sprycel (dasatinib) In Combination With Chemotherapy For Treatment Of Pediatric Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive...

Bristol-Myers Squibb To Take Part In Guggenheim Healthcare Talks Idea Forum

Bristol-Myers Squibb To Take Part In Guggenheim Healthcare Talks Idea Forum

Bristol-Myers Squibb Company (NYSE: BMY) will take part in a fireside chat at the Guggenheim Healthcare Talks Idea Forum on Thursday, February 14, 2019, in New York.

When Everyone Sees the Obvious the Obvious Rarely Happens

Right now it feels as though everyone sees the obvious resistance and overbought situation.

Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal

Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal

Eli Lilly posted weaker-than-expected fourth quarter earnings Tuesday, and lowered its 2019 profit guidance to reflect the impact of its planned acquisition of Loxo Oncology.

Stocks Rise Ahead of Alphabet Earnings

Stocks Rise Ahead of Alphabet Earnings

Stocks rose Monday amid another rush of earnings reports this week including Alphabet results due after the bell.

Report Says Starboard Value Takes Stake in Bristol-Myers

Report Says Starboard Value Takes Stake in Bristol-Myers

Hedge fund Starboard Value took a stake in the company last month, a Bloomberg report says.

Jim Cramer on Starboard's Stake in Bristol-Myers Squibb and Papa Johns

Jim Cramer on Starboard's Stake in Bristol-Myers Squibb and Papa Johns

Jim Cramer reacts to Starboard's stake in Bristol-Myers Squibb and Papa Johns.

Jim Cramer's Thoughts on Google, Starboard's Investments, and Tesla

Jim Cramer's Thoughts on Google, Starboard's Investments, and Tesla

Here's what Jim Cramer thinks about Google's earnings, Starboard's investments and Tesla's acquisition.

Jim Cramer: Tesla, Starboard and Google Earnings

Jim Cramer: Tesla, Starboard and Google Earnings

Jim Cramer weighs in on Starboard's investments, Tesla's purchase and Alphabet's earnings.

Starboard Value Snags Stake in Bristol-Myers Squibb, Says Bloomberg

Starboard Value Snags Stake in Bristol-Myers Squibb, Says Bloomberg

News follows Bristol-Myers Squibb's planned $74 billion buy of Celgene. TheStreet.com could not verify the report.

Bulls vs. Bears: Cramer's 'Mad Money' Recap (Friday 2/1/19)

Bulls vs. Bears: Cramer's 'Mad Money' Recap (Friday 2/1/19)

Jim Cramer makes sense of this market action and has your game plan for next week.

Bank of America, Kemet, Boston Beer: 'Mad Money' Lightning Round

Bank of America, Kemet, Boston Beer: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Bank of America, Kemet, Boston Beer, Diageo, Pilgrim's Pride, Tyson Foods, Moderna and more.

Caterpillar's 'High-Water Mark' Comment in 2018 Puts Finer Focus on 2019 Outlook

Caterpillar's 'High-Water Mark' Comment in 2018 Puts Finer Focus on 2019 Outlook

Management commentary from CAT is key on Monday.

Bristol-Myers Tops Q4 Earnings, Pulls FDA Application for Cancer Combination

Bristol-Myers Tops Q4 Earnings, Pulls FDA Application for Cancer Combination

Bristol-Myers Squibb posts stronger-than-expected fourth-quarter earnings but pulls an application to the U.S. Food and Drug Administration for a blockbuster cancer drug combination in order to collect more data.

Dow Stumbles on Conflicting Signals Over U.S.-China Trade Talks

Dow Stumbles on Conflicting Signals Over U.S.-China Trade Talks

Stocks ended mixed as global investors remain in defensive positions amid ongoing concerns over the strength of the world economy and the fate of U.S.-China trade talks.

What Fools We All Have Become, and Buying Lam Research: Market Recon

What Fools We All Have Become, and Buying Lam Research: Market Recon

Replacing fear with pragmatism, that is our goal.

US Futures Edge Higher on Mixed Earnings; Growth and Trade Concerns Linger

US Futures Edge Higher on Mixed Earnings; Growth and Trade Concerns Linger

U.S. equity futures edged higher Thursday, helped in part by stronger-than-expected semiconductor earnings, even as global investors remained defensive positions amid ongoing concerns over the strength of the world economy, the fate of U.S.-China trade talks and the potential for a change in tack from key central banks.

Ford, Intel, Starbucks, Texas Instruments and Microsoft - 5 Things You Must Know

Ford, Intel, Starbucks, Texas Instruments and Microsoft - 5 Things You Must Know

U.S. stock futures rise modestly as investors retreat largely to defensive positions amid ongoing concerns over the strength of the world economy; Ford swings to a loss because of overseas weakness; Intel, Starbucks and Western Digital report earnings Thursday; Microsoft's Bing search engine is blocked in China.

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

These themes are working despite the turmoil in Washington and slowing global growth.

Bristol-Myers Squibb Reports Fourth Quarter And Full Year Financial Results

Bristol-Myers Squibb Reports Fourth Quarter And Full Year Financial Results

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the fourth quarter and full year of 2018 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (apixaban) and a robust operating performance across the portfolio.

Bristol-Myers Squibb Announces Time Change For Q4 Earnings Results Conference Call

Bristol-Myers Squibb Announces Time Change For Q4 Earnings Results Conference Call

Bristol-Myers Squibb Company (NYSE:BMY) announced today that its fourth quarter 2018 earnings call has been rescheduled for two hours earlier than previously announced.

Global Stocks Stall Amid Growth, Trade Concerns; Wall Street Futures Mixed

Global Stocks Stall Amid Growth, Trade Concerns; Wall Street Futures Mixed

Global stocks stalled Thursday, with investors largely retreating to defensive positions amid ongoing concerns over the strength of the world economy, the fate of U.S.-China trade talks and the potential for a change in tack from key central banks.

Jim Cramer: What Are We to Make of Today's Market Decline?

Jim Cramer: What Are We to Make of Today's Market Decline?

Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Big pharma is shaping up to be a consolidating category in 2019.

New Rules for This Market: Cramer's 'Mad Money' Recap (Friday 1/18/19)

New Rules for This Market: Cramer's 'Mad Money' Recap (Friday 1/18/19)

Jim Cramer's new rules of the road will help investors stay on course and avoid common mistakes. Plus, he's got your game plan.

Banks Are Leading: Cramer's 'Mad Money' Recap (Wednesday 1/16/19)

Banks Are Leading: Cramer's 'Mad Money' Recap (Wednesday 1/16/19)

Jim Cramer looks at the run in the financial stocks and says banks are leading this market back.

Ligand Pharmaceuticals Tumbles After Short-Seller Andrew Left Slams the Stock

Ligand Pharmaceuticals Tumbles After Short-Seller Andrew Left Slams the Stock

Left's firm Citron Research gives the $100+ stock a $35 price target.

Real Money Post-Industrial Average Records 7% Gain So Far in 2019

Real Money Post-Industrial Average Records 7% Gain So Far in 2019

The RMPIA is once again outpacing the S&P 500, Dow Jones Industrial Average and the Nasdaq Composite Index.

TheStreet Quant Rating: C+ (Hold)